Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Discussing Paxil Pediatric Suicide Link With FDA; Label Change In U.K.

Executive Summary

GlaxoSmithKline is discussing with FDA whether Paxil data indicating an increased risk of "emotional lability" in pediatric patients on paroxetine should be communicated to physicians
Advertisement

Related Content

FDA Action On Antidepressants Questioned; Congress Widens Investigation
FDA Requests Antidepressant Labeling Add Suicidality Warning
FDA Action On Antidepressants Questioned; Congress Widens Investigation
FDA Requests Antidepressant Labeling Add Suicidality Warning
Antidepressant Warnings On Pediatric Suicide Need Immediate Strengthening
Antidepressant Warnings On Pediatric Suicide Need Immediate Strengthening
Wyeth Effexor Label Revised With Suicide-Related Adverse Events Precaution
Wyeth Effexor Label Revised With Suicide-Related Adverse Events Precaution
GSK Paxil Pediatric Safety Concerns Have No Effect On Adult Use, FDA Says
GSK Paxil Pediatric Safety Concerns Have No Effect On Adult Use, FDA Says
Advertisement
UsernamePublicRestriction

Register

PS041964

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel